Radiation plus immunotherapy shows promise for tough melanoma
NCT ID NCT01416831
First seen May 07, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study compares two treatments for metastatic melanoma that has spread: high-dose immunotherapy (IL-2) alone versus the same immunotherapy plus targeted radiation (SBRT). The goal is to see if adding radiation helps shrink tumors better. 44 adults with up to 3 tumors that can be safely radiated are enrolled. This is a Phase 2 trial, so it tests effectiveness and safety, but it is not a cure—patients may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Providence Cancer Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.